Lawrence Afrin

Dr. Lawrence Afrin

AIM Center for Personalized Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LALawrence Afrin
Lawrence Afrin
LWLeonard B. Weinstock
Leonard B. Weinstock
GMGerhard J. Molderings
Gerhard J. Molderings
One-fifth of Covid-19 patients suffer a severe course of Covid-19 infection; however, the specific causes remain unclear. Mast cells (MCs) are activated by SARS-CoV-2. Although only recently recognized, MC activation syndrome (MCAS), usually due to acquired MC clonality, is a chronic multisystem disorder with inflammatory and allergic themes, and an estimated prevalence of 17%. This paper describes a novel conjecture explaining how MCAS might cause a propensity for severe acute Covid-19 infection and chronic post-Covid-19 illnesses. Observations of Covid-19 illness in patients with/without MCAS were compared with extensive clinical experience with MCAS. The prevalence of MCAS is similar to that of severe cases within the Covid-19-infected population. Much of Covid-19’s hyperinflammation is concordant with manners of inflammation which MC activation can drive. Drugs with activity against MCs or their mediators have preliminarily been observed to be helpful in Covid-19 patients. None of the authors’ treated MCAS patients with Covid-19 suffered severe infection, let alone mortality. Hyperinflammatory cytokine storms in many severely symptomatic Covid-19 patients may be rooted in an atypical response to SARS-CoV-2 by the dysfunctional MCs of MCAS rather than a normal response by normal MCs. If proven, this theory has significant therapeutic and prognostic implications.

23 September 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LWLeonard B. Weinstock
Leonard B. Weinstock
JBJill B. Brook
Jill B. Brook
AWArthur S. Walters
Arthur S. Walters
AGAshleigh Goris
Ashleigh Goris
LALawrence Afrin
Lawrence Afrin
GMGerhard J. Molderings
Gerhard J. Molderings
Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC. Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were ≥18 years of age and never had overt COVID-19 symptoms. There were 136 LC subjects (89.7% females, age 46.9 ±12.9 years), 136 controls (65.4% females, age 49.2 ±15.5), and 80 MCAS patients (85.0% females, age 47.7 ±16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis. MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.

Verified
Journal Article
Open access
PDF file
AAAnupam Aich
Anupam Aich
LALawrence Afrin
Lawrence Afrin
KGKalpna Gupta
Kalpna Gupta
Mast cells are tissue-resident immune cells that release immuno-modulators, chemo-attractants, vasoactive compounds, neuropeptides and growth factors in response to allergens and pathogens constituting a first line of host defense. The neuroimmune interface of immune cells modulating synaptic responses has been of increasing interest, and mast cells have been proposed as key players in orchestrating inflammation-associated pain pathobiology due to their proximity to both vasculature and nerve fibers. Molecular underpinnings of mast cell-mediated pain can be disease-specific. Understanding such mechanisms is critical for developing disease-specific targeted therapeutics to improve analgesic outcomes. We review molecular mechanisms that may contribute to nociception in a disease-specific manner.

9 April 2020 in Diagnosis
Verified
Journal Article
Open access
PDF file
LALawrence Afrin
Lawrence Afrin
MAMary B. Ackerley
Mary B. Ackerley
LBLinda S. Bluestein
Linda S. Bluestein
JBJoseph Brewer
Joseph Brewer
JBJill B. Brook
Jill B. Brook
GMGerhard J. Molderings
Gerhard J. Molderings
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of “mast cell activation syndrome” (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus” (re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as “consensus-2”), resembling “consensus-1” in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by “consensus-2” criteria has potential to be problematic, but underdiagnosis by “consensus-1” criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.

1 March 2017 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
LALawrence Afrin
Lawrence Afrin
SSSally Self
Sally Self
JMJeremiah Menk
Jeremiah Menk
JLJohn Lazarchick
John Lazarchick

23 April 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LWLeonard B. Weinstock
Leonard B. Weinstock
LPLaura A. Pace
Laura A. Pace
ARAli Rezaie
Ali Rezaie
LALawrence Afrin
Lawrence Afrin
GMGerhard J. Molderings
Gerhard J. Molderings